Merck & Co., Inc. (MRK) Tops Q1 EPS by 2c, Revs Light; Reaffirms Outlook

Merck & Co., Inc. (NYSE: MRK) reported Q1 EPS of $0.99, $0.02 better than the analyst estimate of $0.97. Revenue for the quarter came in at $11.73 billion versus the consensus estimate of $11.82 billion.

Merck & Co., Inc. reaffirmed FY2012 guidance.

For earnings history and earnings-related data on Merck & Co., Inc. (MRK) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Laser Photonics Corporation (LASE) Reports Q2 Loss of $0.08
• Citius Pharmaceuticals (CTXR) Misses Q3 EPS by 37c